Recent therapeutic advances in chronic lymphocytic leukemia [version 1; referees: 2 approved]
The last several years have witnessed a paradigm shift in the management of patients with chronic lymphocytic leukemia (CLL). The course of this very heterogeneous disease, traditionally treated with chemotherapeutic agents usually in combination with rituximab, typically has been characterized by r...
| Hlavní autoři: | , |
|---|---|
| Médium: | Článek |
| Jazyk: | English |
| Vydáno: |
F1000 Research Ltd
2017-10-01
|
| Edice: | F1000Research |
| Témata: | |
| On-line přístup: | https://f1000research.com/articles/6-1924/v1 |